268 related articles for article (PubMed ID: 28589395)
21. Prostate magnetic resonance imaging findings in patients treated for testosterone deficiency while on active surveillance for low-risk prostate cancer.
Hashimoto T; Rahul K; Takeda T; Benfante N; Mulhall JP; Hricak H; Eastham JA; Vargas HA
Urol Oncol; 2016 Dec; 34(12):530.e9-530.e14. PubMed ID: 27665357
[TBL] [Abstract][Full Text] [Related]
22. Testosterone Therapy and Prostate Cancer: Incorporating Low-Level Evidence into Practical Recommendations.
Morales A; Siemens DR
Urol Clin North Am; 2022 Nov; 49(4):573-582. PubMed ID: 36309414
[TBL] [Abstract][Full Text] [Related]
23. Testosterone therapy in prostate cancer: is it still a controversy?
Bart AS; Van Hoof A; Badre-Hume R; Selvarajah J; Robillard K; Albala DM
Curr Opin Urol; 2022 Nov; 32(6):598-606. PubMed ID: 36081393
[TBL] [Abstract][Full Text] [Related]
24. The role of testosterone replacement therapy following radical prostatectomy.
Khera M; Lipshultz LI
Urol Clin North Am; 2007 Nov; 34(4):549-53, vi. PubMed ID: 17983894
[TBL] [Abstract][Full Text] [Related]
25. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
26. Testosterone, testosterone therapy and prostate cancer.
Yassin A; AlRumaihi K; Alzubaidi R; Alkadhi S; Al Ansari A
Aging Male; 2019 Dec; 22(4):219-227. PubMed ID: 30614347
[TBL] [Abstract][Full Text] [Related]
27. Point: urologists should take an active role in the diagnosis and treatment of hypogonadism in the aging male.
Heaton JP
Can J Urol; 2002 Dec; 9(6):1677-80. PubMed ID: 12517308
[TBL] [Abstract][Full Text] [Related]
28. Testosterone therapy for men at risk for or with history of prostate cancer.
Morgentaler A
Curr Treat Options Oncol; 2006 Sep; 7(5):363-9. PubMed ID: 16904053
[TBL] [Abstract][Full Text] [Related]
29. A rational approach to androgen therapy for hypogonadal men with prostate cancer.
Kaufman J
Int J Impot Res; 2006; 18(1):26-31. PubMed ID: 16208401
[TBL] [Abstract][Full Text] [Related]
30. Effects of 8-Year Treatment of Long-Acting Testosterone Undecanoate on Metabolic Parameters, Urinary Symptoms, Bone Mineral Density, and Sexual Function in Men With Late-Onset Hypogonadism.
Permpongkosol S; Khupulsup K; Leelaphiwat S; Pavavattananusorn S; Thongpradit S; Petchthong T
J Sex Med; 2016 Aug; 13(8):1199-211. PubMed ID: 27436076
[TBL] [Abstract][Full Text] [Related]
31. Is there a protective role of testosterone against high-grade prostate cancer? Incidence and severity of prostate cancer in 553 patients who underwent prostate biopsy: a prospective data register.
Yassin A; Salman M; Talib RA; Yassin DJ
Aging Male; 2017 Jun; 20(2):125-133. PubMed ID: 28282997
[TBL] [Abstract][Full Text] [Related]
32. Safety of androgen therapy in men with prostate cancer.
Rajan P; Tharakan T; Chen R
Best Pract Res Clin Endocrinol Metab; 2022 Sep; 36(5):101628. PubMed ID: 35248487
[TBL] [Abstract][Full Text] [Related]
33. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia.
Rhoden EL; Morgentaler A
J Urol; 2003 Dec; 170(6 Pt 1):2348-51. PubMed ID: 14634413
[TBL] [Abstract][Full Text] [Related]
34. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men.
Debruyne FM; Behre HM; Roehrborn CG; Maggi M; Wu FC; Schröder FH; Jones TH; Porst H; Hackett G; Wheaton OA; Martin-Morales A; Meuleman E; Cunningham GR; Divan HA; Rosen RC;
BJU Int; 2017 Feb; 119(2):216-224. PubMed ID: 27409523
[TBL] [Abstract][Full Text] [Related]
35. The effects of testosterone replacement therapy on the prostate: a clinical perspective.
Miah S; Tharakan T; Gallagher KA; Shah TT; Winkler M; Jayasena CN; Ahmed HU; Minhas S
F1000Res; 2019; 8():. PubMed ID: 30828436
[TBL] [Abstract][Full Text] [Related]
36. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
Morgentaler A; Rhoden EL
Urology; 2006 Dec; 68(6):1263-7. PubMed ID: 17169647
[TBL] [Abstract][Full Text] [Related]
37. Critical Update of the 2010 Endocrine Society Clinical Practice Guidelines for Male Hypogonadism: A Systematic Analysis.
Seftel AD; Kathrins M; Niederberger C
Mayo Clin Proc; 2015 Aug; 90(8):1104-15. PubMed ID: 26205546
[TBL] [Abstract][Full Text] [Related]
38. A new era of testosterone and prostate cancer: from physiology to clinical implications.
Khera M; Crawford D; Morales A; Salonia A; Morgentaler A
Eur Urol; 2014 Jan; 65(1):115-23. PubMed ID: 24011426
[TBL] [Abstract][Full Text] [Related]
39. Prevention of prostate cancer by androgens: experimental paradox or clinical reality.
Algarté-Génin M; Cussenot O; Costa P
Eur Urol; 2004 Sep; 46(3):285-94; discussion 294-5. PubMed ID: 15306098
[TBL] [Abstract][Full Text] [Related]
40. To treat or not to treat with testosterone replacement therapy: a contemporary review of management of late-onset hypogonadism and critical issues related to prostate cancer.
Kava BR
Curr Urol Rep; 2014 Jul; 15(7):422. PubMed ID: 24832199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
